KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients

“…35 With regard to AEs, CFZ has been shown to have less off-target activity against enzymes other than those in the proteasome and immunoproteasome, 36 and this may be associated with the different toxicity profile of CTZ compared with BTZ; for example, the low incidence of PN. [6][7][8][9][10][11][12][13][14] Hematological AEs were most common in our cohort, and there was no significant difference in the frequencies of hematologic AEs with KRD and KD therapy. Regarding nonhematologic AEs, a high frequency of CVAEs has been a critical concern in use of CFZ for myeloma.…”

“…Information on the prognostic impact of prior resistance to BTZ and/or LEN in KRD therapy is also limited in real-world observational studies, [11][12][13] while such information is mostly lacking for KD therapy.…”

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

“…12 Similarly, the addition of elotuzumab to Rd reduced the risk of progression by 30%, with a gain of 4.5 progression-free months compared with the control arm. 14 In this current study, in the lack of a randomized KRd vs. EloRd trial, and with the well-known limitations and susceptibility to the bias of real-life suggestions, 17 we weighed the relative usefulness of one triplet over the other, comparing a multicenter retrospective EloRd cohort 18 with four multicenter retrospective KRd cohorts, [19][20][21][22] all including RRMM cases treated outside of clinical trials. This current clinical practice study's overall results demonstrate that KRd therapy offers a superior outcome than EloRd.…”

“…After twelve cycles, K was reduced (days 1, 2, 15, and 16) and prolonged beyond 18 cycles at the physician's discretion. [19][20][21][22] In all five cohorts (EloRd and KRd), the dose of each drug was adjusted according to drug recommendations in case of specific preexisting comorbidities. In cases of specific predefined hematological and non-hematological toxic events, drugs' dosages were reduced, according to the manufacturers' recommendations and medical choice.…”

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma

“…[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] In this respect, the first and subsequent treatment lines are enriched with a suitable combination of these novel agents in doublets, triplets, and quadruplets, with proper class shift scheduling. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Novel chimeric antigen receptor (CAR) T cell-based therapies, 17 along with anti-B-cell maturation antigen (BCMA) antibody-drug conjugates, bispecific antibodies, and bispecific T cell engagers (BiTEs), 18 produce renewed expectation for MM patients. Novel antibody constructs, such as belantamab mafodotin, 19 can be considered after repeated relapses.…”